Pheon Therapeutics’ Post

Pheon is #hiring! Please check out our latest role, Clinical Trial Lead, and send your CVs to [email protected]. #Recruiting #ClinicalTrialLead

📣 Pheon Therapeutics announces the closing of a $120m Series B financing to fund development of its differentiated #ADC pipeline!

NEWS ALERT! 📣 We are excited to announce the completion of a $120 million Series B financing to advance our differentiated #ADC pipeline through clinical proof of concept⚕. Our first three assets are aimed at an undisclosed novel target that is highly overexpressed in a wide range of #solidtumors   This funding round is led by TCGX, with new investments from BVF PARTNERS, L.P, Lightspeed Venture Partners, and Perceptive Advisors, alongside continued support from Atlas Venture, Brandon Capital, Forbion, and Research Corporation Technologies, Inc..   As part of this milestone, we welcome Cariad Chester, Managing Partner of TCGX, to our highly experienced board of directors.   Stay tuned 🔊 for further updates as we prepare to transition into the clinic with our lead program later this year in a Phase 1 clinical trial!   For more details, refer to the press release linked in the comments below.

Pheon Therapeutics is set to be in San Francisco from 8-11 January at the 42nd Annual J.P. Morgan Healthcare Conference. Please get in touch to schedule a meeting with our CEO, Cyrus Mozayeni and discover more about #Pheon's innovative approach to #ADCs with the potential to improve outcomes for patients facing hard-to-treat cancers. Visit our website: pheontx.com #JPM2024 #PheonTherapeutics #Oncology #Innovation 

We’re #hiring! Please check out our new role here

Next week, Pheon Therapeutics CEO Cyrus Mozayeni, and VP of R&D and co-founder Paul Jackson will be in London, attending LSX - partnering for Life Science eXecutives Inv€$tival Showcase and Jefferies London Healthcare Conference from the 13-16 November.   CEO, Cyrus Mozayeni will be present at #LSX on the 'Biotech Late Growth' stage on Monday, November 13 at 13.45 GMT and will share insights on #Pheon's pipeline of next-generation #ADCs.   Following LSX, the team will be attending the #Jefferies London Healthcare Conference from November 14 - 16, the largest healthcare-dedicated conference in Europe.   Please get in touch if you're interested in learning more about Pheon's groundbreaking approach to ADCs with the potential to to improve outcomes for patients facing hard-to-treat cancers.   #LSXInvestival #JefferiesHealthcareConference #PheonTherapeutics  

Pheon Therapeutics is pleased to announce its CEO, Cyrus Mozayeni will be presenting at the LSX - partnering for Life Science eXecutives Inv€$tival Showcase on November 13 in London.   Cyrus will present on the 'Biotech Late Growth' stage at 13.45pm GMT and will share #Pheon's latest advancements of its wholly owned, proprietary #ADCs targeting solid tumors as the Company prepares to transition into clinical development.    LSX Inv€$tival is the premier networking and pitching event for early and growth-stage companies and is part of the most important week in European healthcare investment.   Visit the Pheon website to learn more about its next-generation ADC pipeline which aims to treat cancers with significant unmet need: pheontx.com.   #LSXInvestival #PheonTherapeutics

We are pleased to announce the appointment of #oncology expert Arvin Yang, MD, PhD as Pheon Therapeutics Chief Medical Officer.   Dr. Yang is a seasoned CMO, who joins Pheon with over a decade of experience in leading therapeutic oncology products through early-stage #clinical development, and late-stage global registration trials. His deep knowledge of oncology clinical development will be invaluable as we look to advance our first-in-class #ADCs for the treatment of solid tumors.   Read more about Dr. Yang's experience and what he will bring to #Pheon, here: https://bit.ly/45qaxJE   #PheonTherapeutics #oncology #CompanyGrowth #clinicaldevelopment